BANKRUPTCY PLAYS

[I Like Bottom Fishing]

Hi how are you mattchew, i have been fine, but this osciq chart play has had me confuse i can't figure this one out that MM nite has been the main one holding it down, they have been trying and doing every trick in the book to hold osciq back.

Here are some osciq charts with the 5,10,20,30,50 sma/ema sernearo. This one has me confuse.










































































Now after I look at the level2 more closely the MM nite may want to take this down to 0.05 or all the way down to 0.04 and bring it to the high of 0.09 0.127 0.15 may be that MM nite wants enough power to go to fill those gaps at 0.175? humm!
Level2 Trying to paint the closing ticket at 0.058 or 0.06 MM nite holing back the trade, No trade on time and sells, What is going here with MM nite.

OSCIQ - Cornerstone Wins Factive Rights

Wednesday, September 09, 2009 07:10ET

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

http://www.knobias.com/story.htm?eid=3.1.292501a83d38112652edf195b6aa5a19325377d546bf991a52662f8002f55847

Sep 09, 2009 (Zacks.com via COMTEX) -- Last week, Cornerstone Therapeutics Inc. (CRTX) announced the receipt of approval from the United States Bankruptcy Court for Massachusetts district regarding the acquisition of Factive's (gemifloxacin mesylate) commercial rights in North America and some European countries from Oscient Pharmaceuticals Corp., which filed for Chapter 11 bankruptcy protection in July.

The transaction is worth $5 million in cash. Additionally, it includes an amount for purchased inventory, quarterly royalty payments based on adjusted net sales for a period of five years, and the assumption of certain liabilities.

Factive, which belongs to the fluoroquinolone class of antibiotics, is indicated for the treatment of community-acquired pneumonia (CAP) of mild to moderate severity and acute bacterial exacerbations of chronic bronchitis (ABECB). It was launched in the U.S. in September 2004 and is the only fluoroquinolone approved in the U.S. for the five-day treatment of both ABECB and CAP.

Factive has generated approximately 1.1 million prescriptions since its launch. It garnered approximately $16 million net revenues in 2008.

As a reminder, Cornerstone Therapeutics Inc was established through the merger of Critical Therapeutics with Cornerstone Biopharma Holdings Inc in the fourth quarter of 2008. The company has a wide range of products in its portfolio including AlleRx for allergic rhinitis; Balacet 325 for pain; Spectracef, an oral antibiotic for infections; and Zyflo/Zyflo CR for asthma. The company has a deep late-stage clinical pipeline with quite a few regulatory approval submissions expected between 2009 and 2011.

Cornerstone's $70 million deal with Chiesi Farmaceutici, an Italian pharmaceutical firm, further broadens its product portfolio. The deal includes U.S. rights to the Chiesi drug Curosurf, which is used to treat respiratory distress syndrome (RDS) in premature babies.

The inclusion of Factive is an impressive addition to the already accomplished portfolio, and strengthens its presence in the respiratory market. Cornerstone operates in a highly competitive respiratory market. Its products compete with both big players and generic counterparts. However, we believe the company's strategy is to carve a niche in this market. Cornerstone's top competitors include big players like AstraZeneca (AZN), GlaxoSmithKline plc (GSK) and Merck (MRK).

Get real-time market insights and profitable stock recommendations from the team of analysts at Zacks Investment Research.See all today's Analyst Blog entries.

Zacks Equity Research

Copyright (C) 2009, Zacks Investment Research.


Public Companies Associated with this story:
CRTXD OSCIQ

Content transmitted by Knobias.com Copyright © 2009 Visit Knobias.com

http://www.knobias.com/individual/public/quote.htm?ticker=OSCIQ

http://www.knobias.com/story.htm?eid=3.1.292501a83d38112652edf195b6aa5a19325377d546bf991a52662f8002f55847

ABOUT | PARTNERS | ADVERTISING INFO | CONTACT US | COPYRIGHT | PRIVACY | LEGAL | DISCLAIMER
Copyright © 2009 Knobias.Com, LLC. All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Knobias.Com, LLC, nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Knobias.Com website(s), a user agrees not to redistribute the information found therein. Knobias.Com, LLC is not a registered broker-dealer and does not endorse or recommend any securities listed herein or any services of any brokerage company.